CAJ | 학술논문

目的:分析Caspase-8在非小细胞肺癌组织中的表达和临床意义.方法:采取免疫组织化学法进行检测非小细胞肺癌中的Caspase-8蛋白表达水平.结果:通过临床的实验分析,在患者的癌组织中检测Caspase-8的阳性率为64.7%,正常的组织中检测Caspase-8的阳性率为73.5%,其中组间的对比无明显的差异(P>0.05),统计学无意义.但是组间Caspase-8蛋白的表达强度和细胞内的定位比较存在明显的差异(P<0.05),统计学有意义;而组织中的Caspase-8蛋白表达与患者的病理类型、组织学类型、是否吸烟、性别与年龄等无明显的联系.但是Caspase-8蛋白的表达与淋巴结的转移、临床的分期以及患者的生存期等有着密切的关系,数据的比较具有明显的差异(P<0.05),统计学有意义.结论:在非小细胞肺癌的组织中Caspase-8蛋白表达强度明显,并且与非小细胞肺癌的淋巴结的转移和临床的分期以及患者的生存期有着密切的关系,可作为一种新型的非小细胞肺癌诊断标志物.
목적:분석Caspase-8재비소세포폐암조직중적표체화림상의의.방법:채취면역조직화학법진행검측비소세포폐암중적Caspase-8단백표체수평.결과:통과림상적실험분석,재환자적암조직중검측Caspase-8적양성솔위64.7%,정상적조직중검측Caspase-8적양성솔위73.5%,기중조간적대비무명현적차이(P>0.05),통계학무의의.단시조간Caspase-8단백적표체강도화세포내적정위비교존재명현적차이(P<0.05),통계학유의의;이조직중적Caspase-8단백표체여환자적병리류형、조직학류형、시부흡연、성별여년령등무명현적련계.단시Caspase-8단백적표체여림파결적전이、림상적분기이급환자적생존기등유착밀절적관계,수거적비교구유명현적차이(P<0.05),통계학유의의.결론:재비소세포폐암적조직중Caspase-8단백표체강도명현,병차여비소세포폐암적림파결적전이화림상적분기이급환자적생존기유착밀절적관계,가작위일충신형적비소세포폐암진단표지물.
@@@@Objective:To analyze the Caspase-8 expression in non-small cell lung cancer and clinical significance.Methods:Immunohistochemical method for the detection of non-small cell lung cancer Caspase-8 protein levels.Results:Through the analysis of clinical experiments, detected in patients with cancer organization Caspase-8-positive rate of 64.7%, normal tissue detection of Caspase-8-positive rate of 73.5%, which group the contrast between no significant differences (P>0.05), statistically meaningless. Strength group Caspase-8 protein expression and intracellular localization, there is a significant difference (P<0.05), statistically meaningful;organization of Caspase-8 protein expression in patients with pathological type, histological type, whether smoking, gender and age had no significant contact. Caspase-8 protein expression and lymph node metastasis, clinical staging, as well as the patient’s survival period is closely related data compare with a significant difference (P<0.05), statistically meaningful.Conclusion:Caspase-8 in non-small cell lung cancer tissue protein expression was significantly, and have a close relationship with non-small cell lung cancer lymph node metastasis and clinical staging as well as the patient’s survival time, can be used as a new type of non-small cell lung cancer diagnostic marker.